Good morning. My name is Brittany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Fourth Quarter and Full Year 2023 Financial Results Conference call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. Please be advised that today's conference may be recorded. I would now like to turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.

Thank you, operator. Good morning, everyone. And thank you for joining us today as we review Harmony Biosciences fourth quarter and full year 2023 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany our discussion today, including the reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical Officer; and Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially and we undertake no obligation to update these statements, even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff.

Thank you, Luis. And thanks everyone for joining our conference call today. Harmony continues to be a growth story as demonstrated by our team's accomplishments throughout 2023. We delivered another strong year of performance across the organization, growing revenue and the average number of patients on WAKIX. We advanced all our clinical development programs for pitolisant, moved the next-generation formulations of pitolisant into the clinic, and expanded our pipeline and diversified our portfolio with the acquisition of Zynerba and the ongoing Phase 3 clinical trial in patients with Fragile X syndrome. Yesterday, we announced that the FDA granted priority review for our supplemental NDA for WAKIX in pediatric narcolepsy with a PDUFA date of June 21st. Earlier this week, we also shared that the FDA granted orphan drug designation for pitolisant for the treatment of Prader-Willi Syndrome as we are preparing to initiate our pivotal Phase 3 TEMPO study in patients with PWS down to age six. All of this reflects momentum across our organization from our commercial business with WAKIX in narcolepsy to our clinical development programs, as well as positive interactions with FDA related to these programs. These outcomes also reflect excellence in execution, and the dedication of our team to deliver on the strategy we have laid out and are executing on. In addition, we have returned capital to shareholders via our share repurchase program and will continue to take an opportunistic approach to this program throughout this year. I am very excited for the year ahead and believe that Harmony is poised to accelerate our growth in 2024. For the fourth quarter, we reported WAKIX net revenue of $168.4 million and full year net revenue was $582 million, representing growth of 31% and 33% respectively. This result demonstrates the significant underlying demand for WAKIX and the durability of the brand going into year five in the market. Other factors that drive our confidence in our ability to grow WAKIX include its meaningfully differentiated product profile, which results in its broad clinical utility, in addition to our ability to reach the broad prescriber universe of approximately 9,000 healthcare professionals who see and treat almost 100% of the diagnosed narcolepsy patient opportunity. We have seen growth in patients on WAKIX and prescribers every quarter since launch, even with the entrance of new branded and generic oxybate treatment options coming into the market over the past few years. Finally, while there are several investigational agents in the clinic for narcolepsy, we do not see any new or novel mechanisms of action coming to the market that will impact the growth of WAKIX until later during its life cycle in this polypharmacy market. Based on these reasons, along with the vast market opportunity that remains in narcolepsy, we believe that we can continue to grow the franchise for years to come and remain confident that WAKIX represents a $1 billion plus opportunity in adult narcolepsy alone. This is evidenced by our net revenue guidance for 2024 ranging from $700 million to $720 million. In addition to our strong commercial performance, we also advanced and expanded our clinical development enterprise on several fronts. Kumar will provide more details on our clinical development program later in the call. But first, let me highlight some of our progress. Starting with pediatric narcolepsy, we are pleased that the FDA granted priority review for our sNDA for WAKIX. This expedites the review process, and the FDA has set a PDUFA date of June 21st. We look forward to collaborating with the agency to potentially introduce a new non-scheduled treatment option for pediatric patients living with narcolepsy. Turning to idiopathic hypersomnia. After completing our review of the full data set, we continue to believe that based on the totality of the data, along with pitolisant receiving orphan drug designation for IH and against the backdrop of only one currently approved product that there is a strong case to be made regarding the overall benefit-risk proposition of pitolisant for patients with IH. We will be engaging with the agency with this goal in mind, have a meeting scheduled with them next month and look forward to working with the agency on bringing a potential new non-scheduled treatment option to patients living with IH. Our current lifecycle management programs for pitolisant, which include IH, Prader-Willi syndrome, and type 1 myotonic dystrophy, represent about a hundred thousand diagnosed patients in the US. So if successful, these new indications could contribute up to an additional $1 billion of revenue to the WAKIX franchise. Given pitolisant's novel mechanism of action and the success of WAKIX in the market, we've been working on next-gen formulations of pitolisant with the goal to generate new intellectual property and extend the pitolisant franchise out beyond 2040. These programs entered the clinic last quarter and we are on track to report pharmacokinetic data in the first half of this year. Another key component of our growth strategy is business development to expand our pipeline beyond WAKIX and diversify our portfolio beyond sleep-wake disorders. The Zynerba acquisition, which closed last October, represented an important step in that direction and was an excellent strategic fit for Harmony, bringing in two late-stage development programs focused on rare neuropsychiatric disorders with significant unmet medical needs. And we are not stopping with the Zynerba acquisition and remain very active in business development, continually assessing the landscape with a focus on rare neurological disease assets and other rare disease assets with unmet medical needs where we can leverage our existing infrastructure and synergies across our organization. We are looking for assets across a range of development stages with a preference for late-stage assets but open to early-stage assets where there is a strategic fit. With approximately $426 million in cash, cash equivalents, and investments at year-end, we are in a solid financial position to execute on business development opportunities, which is a strategic priority for us. In conclusion, I am proud of our team's accomplishments in 2023 and what we were able to do to help patients living with narcolepsy while advancing our development programs in other rare disease patient populations. We experienced solid and durable growth in our core commercial business, strong momentum in our clinical development programs, and expansion and diversification of our pipeline assets. Based on the dedication and commitment across our organization, I am very excited for our opportunities in 2024 as we remain focused on developing and commercializing innovative treatments for patients living with rare neurological diseases who have unmet medical needs. I will now turn the call over to Jeffrey Dierks, our Chief Commercial Officer to provide more details on our commercial performance. Jeff?

Thank you, Jeff. 2023 was a strong year of growth for WAKIX and year four of our commercialization in adult narcolepsy. The fourth quarter represented the strongest revenue quarter in our history with continued growth and momentum in our underlying business fundamentals and top-line performance metrics. Net revenue for the fourth quarter was $168.4 million, representing 31% growth from the same quarter prior year and our second consecutive quarter of over $150 million in net revenue. Full-year 2023 net revenue was $582 million, a 33% increase from full year 2022. We continue to see strong double-digit growth in net revenue for WAKIX heading into year five of our commercialization, reflecting continued high interest in WAKIX in the narcolepsy market. The solid performance and continued growth reinforce our long-term belief that WAKIX represents a potential billion-dollar opportunity in adult narcolepsy alone. I'd like to share a few key highlights from our performance in the fourth quarter. The average number of patients on WAKIX in the fourth quarter increased to approximately 6,150, an increase of approximately 350 average patients sequentially from what we reported last quarter. The impressive growth in average patients in the fourth quarter was driven by strong top-line demand and new patient starts and speaks to continued product adoption. And, more importantly, it highlights the remaining large diagnosed patient opportunity that we continue to tap into each quarter as the market allows. In addition to the strong growth in average number of patients on WAKIX, we also saw continued product adoption of WAKIX by the narcolepsy healthcare community, both in new and existing prescribers. The number of unique prescribers of WAKIX increased again in the fourth quarter, and importantly, we continue to see growth in product adoption of WAKIX in the prescriber base beyond oxybate REMS enrolled healthcare professionals. Of the approximately 5,000 healthcare professionals not enrolled in the oxybate REMS program, more than 30% of them have prescribed WAKIX to date, up from 25% reported on our last earnings call. In addition to the continued growth of our prescriber base, we also saw strong growth in the depth of prescribing within the approximately 4,000 oxybate REMS enrolled healthcare professionals. Our ability to reach and educate the broad narcolepsy treating healthcare professional universe allows us to access the full diagnosed adult narcolepsy patient opportunity and gives us confidence in continued growth for WAKIX. The availability of new and generic oxybates hasn't impacted patient or prescriber growth or existing strong payer coverage for WAKIX given its meaningfully differentiated product profile. WAKIX remains the first and only FDA-approved treatment for excessive daytime sleepiness and cataplexy in narcolepsy that is not scheduled as a controlled substance, an attribute that continues to appeal to our broader narcolepsy healthcare professional audience and patient population and is a driver of brand growth. In summary, 2023 was another year of strong commercial performance for WAKIX. Full-year net revenue of $582 million, 33% growth versus the full-year 2022. The fourth quarter represented the strongest revenue quarter for Harmony to date with over $168 million in net revenue. The average number of patients on WAKIX increased to approximately 6,150. The WAKIX prescriber base within and beyond oxybate REMS enrolled healthcare professional audience continued to grow. And lastly, payer coverage remains strong even with the availability of new engineered oxybate options. WAKIX continues to demonstrate durable growth in the narcolepsy market. We've seen growth in patients and prescribers every quarter since launch, even with branded and generic treatment availability and new launches during its first four years on the market. Looking ahead to 2024, we expect continued growth in the underlying business fundamentals for WAKIX with net revenues expected to be between $700 million and $720 million. We anticipate a similar quarterly rhythm to our business in 2024 with what we've experienced in previous years. Traditional seasonal payer dynamic headwinds that impact the entire industry as a whole in Q1, tailwinds coming out of Q1 and Q2 with stronger prescription demand, typical seasonal headwinds in Q3 with lower patient visits that are common for all products and diseases that are chronically managed, and tailwinds in the fourth quarter as we close out the year. With no new competition expected in 2024 and limited differentiation in generic and branded products in the near-term pipeline, coupled with the large remaining diagnosed patient opportunity, unmet needs, and the polypharmacy nature of the narcolepsy market, WAKIX is well positioned for continued growth. Our ability to educate the broad REMS and non-REMS narcolepsy treating healthcare professional audience and ability to tap into the full diagnosed patient opportunity gives us confidence in the long-term potential for the brand to represent a billion-dollar opportunity in adult narcolepsy alone. Our commercial business has been resilient. And I appreciate the dedication and impact of the entire commercial team and the passion that they have for the narcolepsy patient community. I would like to now turn the presentation over to Kumar Budur, our Chief Medical Officer, to provide an update on our clinical development pipeline. Kumar?

Thank you, Jeff. Last year was a defining year for Harmony R&D. We made great progress in advancing, expanding, and diversifying our portfolio, working on nine different development programs across five different assets, several of which are in late-stage development. It is not just the numbers but also the complexity of the programs as we target a broad set of indications in rare disease patient populations with significant unmet medical needs. As we grew our portfolio, we also built a strong, experienced, and dedicated R&D organization ready to take on new opportunities as we continue to build our existing portfolio with new assets via business development. I'm proud of the work that our team does every day and look forward to delivering potential new treatment options for patients with rare diseases with high unmet needs. Our full clinical development pipeline is shown on Slide number 7. Starting with pediatric narcolepsy, we submitted a supplemental NDA to the FDA for an indication in pediatric narcolepsy in the fourth quarter and we are pleased with the FDA's decision to grant a priority review. This decision highlights the need for new treatment options for the approximately 4,000 pediatric patients living with narcolepsy. The FDA has set a PDUFA date of June 21st. We look forward to working with the FDA to potentially bring a non-scheduled treatment option administered once a day in the morning for pediatric patients with narcolepsy. Moving on to our development program in idiopathic hypersomnia, we completed our review of the full data set and submitted an FDA meeting request in the fourth quarter to discuss the path forward and the meeting is scheduled for March. We are optimistic that we'll be able to find an efficient path forward to bring pitolisant to patients with idiopathic hypersomnia. Our optimism is based on the totality of the data which strongly supports pitolisant's efficacy in patients with idiopathic hypersomnia, especially in the context of high unmet need with only one drug approved, which is a scheduled Class III controlled substance with our REMS program and the off-label use of Class II controlled stimulant with significant safety issues. The data from the open-label part of the study, double-blind randomized withdrawal part of the study, and the ongoing long-term extension study in conjunction with the benign safety profile offer a strong benefit proposition in favor of pitolisant for patients with idiopathic hypersomnia. We look forward to engaging with the FDA in the meeting scheduled next month and making a strong case for a positive benefit profile for pitolisant in idiopathic hypersomnia. We will provide further updates on the IH program at our next earnings call. For Prader-Willi syndrome, we are on track to initiate the Phase 3 TEMPO study in the first quarter of this year. This will be a global double-blind randomized placebo-controlled study that will randomize approximately 134 patients to either pitolisant or placebo in a 1:1 ratio. The duration of the double-blind treatment period is 11 weeks. The age range is six years and older and the primary endpoint is change in severity of excessive daytime sleepiness as measured by PROMIS SRI T-score from baseline to the end of the double-blind treatment period compared to placebo. Based on the promising data from the Phase 2 proof-of-concept study, we are also evaluating the irritable and disruptive behaviors which are common in PWS. This Phase 3 registration study is designed not just to meet the requirements for an indication in PWS but also to fulfill one of the two requirements to gain pediatric exclusivity. We remain confident and committed to gain pediatric exclusivity for WAKIX, which will offer an additional six-month regulatory exclusivity on the back end of the requirements. Based on the discussions with the FDA, we have a clear line of sight on the requirements for our PWR, which include data in pediatric narcolepsy patients and data from the Phase 3 study in PWS. We are making steady progress to meet these requirements. The pediatric narcolepsy sNDA submission in the fourth quarter and the initiation of the Phase 3 PWS study this quarter are designed to support our efforts to gain pediatric exclusivity for WAKIX. In myotonic dystrophy type 1, or DM1, we were pleased to report positive top-line results from the Phase 2 proof-of-concept study where we saw clinically meaningful improvement in not just excessive daytime sleepiness, as measured by the Daytime Sleepiness Scale but also in fatigue, which was assessed using the Fatigue Severity Scale, and these data are summarized on Slide 9. It's important to note that these two symptoms, excessive daytime sleepiness and fatigue are present in approximately 80% to 90% of patients with DM1, and these symptoms are as impactful as a core symptom of myotonia and progressive muscle weakness. A clear and consistent dose-response was also demonstrated with the higher dose showing a greater response than the lower dose across the study endpoints. In addition, the safety profile in this patient population is consistent with the established safety profile of pitolisant. We are currently reviewing the complete data set to assess the opportunity and inform our next steps. As we have noted in the past, this is an indication that could be pivotal to the next-gen pitolisant-based formulation, which will have a much longer patent. We continue to make good progress on the next-gen pitolisant-based formulations with our partner Bioproject with the goal of generating new intellectual property, extending the pitolisant franchise beyond 2040, and bringing new treatment options for people living with rare diseases. Please note we have updated the naming conventions for these two formulations according to their respective market entry timing. Next-gen 1 or NG1 is a modified formulation of pitolisant with the potential for clinical differentiation and a fast market strategy based on the demonstration of bio-equivalence. We expect to launch NG1 within the WAKIX life cycle. Next-gen 2 or NG2 is an enhanced formulation of pitolisant designed to deliver an optimal pharmacokinetic profile and a higher dosage strength. This formulation will have new intellectual property, a full clinical development program, and is expected to be launched toward the end of the WAKIX life cycle. Both formulations, NG-1 and NG-2, entered the clinic in the fourth quarter and we expect PK data on both of them in the first half of this year. We were also pleased to expand and diversify our pipeline last quarter with the acquisition of Zynerba. This brought in ZYN002, a pharmaceutically produced synthetic cannabidiol, devoid of THC for transdermal delivery, which like WAKIX, represents another portfolio in a product opportunity. We are currently enrolling patients in the pivotal Phase 3 RECONNECT trial in Fragile X syndrome, and are very excited about this opportunity. There are approximately 80,000 patients diagnosed with Fragile X syndrome in the US with no approved treatments and significant unmet medical needs. We had an opportunity to assess the timeline of the RECONNECT trial and expect to complete patient enrollment in the first quarter of 2025 with top-line data in mid-2025. ZYN002 was also studied in an open-label Phase 2 proof-of-concept study in patients with 22q deletion syndrome, known as the INSPIRE trial, which generated promising data. This represents another market opportunity of approximately 80,000 patients in the US and we have been interacting with the FDA about the Phase 3 program in 22q. It is worth noting that ZYN002 is a global opportunity for Harmony and we look forward to exploring ex-US opportunities to bring this novel treatment to people living with Fragile X syndrome and 22q around the world. To conclude, we have made great progress at Harmony in advancing, expanding, and diversifying our portfolio, resulting in a pipeline with multiple late-stage programs. I look forward to sharing additional updates as we continue to make progress on our clinical development program. On behalf of Harmony, I would like to thank all the patients and their families who are participating in our clinical trials, as well as the clinical investigators and site personnel for their efforts and commitment in helping us to advance our development programs. I’ll now turn the call over to CFO, Sandip Kapadia, for an update on our financial performance. Sandip.

Thank you, Kumar, and good morning, everyone. This morning, we issued our fourth quarter earnings release and filed our 10-K where you'll find the details of our fourth quarter and full year 2023 financial and operating results. Our financial performance is also shown on Slides 10 through 13. We finished the year with strong momentum across the business, helping us deliver solid growth across several key metrics. We reported $582 million in annual WAKIX net revenue, achieved our third year of profitability along with robust cash generation. In addition, we advanced our pitolisant life cycle management program and executed on business development with the acquisition of Zynerba. We also deployed capital towards our share repurchase program. Overall, we remain well-positioned to execute on our growth strategy moving forward. So let me take a moment to review our financial results in more detail. For the fourth quarter of 2023, we reported our strongest revenue quarter in company history with net revenues of $168.4 million compared to $128.3 million in the prior year quarter, representing a growth of 31%. Performance in the quarter reflects the strong continued underlying demand for WAKIX. In the fourth quarter of 2023, operating expenses were $85.1 million compared to $53.8 million in the prior year quarter. The higher operating expenses were primarily driven by our advancement of our clinical development programs, including ZYN002, expenses related to the commercialization of WAKIX, and one-time Zynerba transaction-related costs of $9.8 million. Operating income for the fourth quarter of 2023 was $40.2 million compared to $47.6 million in the prior year quarter. Non-GAAP adjusted net income for the fourth quarter of 2023 was $42.8 million or $0.73 per diluted share compared to $61.9 million or $1.01 per diluted share in the prior year quarter. We believe non-GAAP adjusted net income better reflects the underlying business performance. Please refer to our press release for a reconciliation of GAAP to non-GAAP results. We ended the year with $425.6 million of cash, cash equivalents, and investment securities on the balance sheet. The balance reflects continued strong cash generation with approximately $77 million in cash from operations in the fourth quarter, offset by the Zynerba acquisition costs and share repurchase activities in the quarter. For the full year 2023, we generated $219 million in cash from operations. During the fourth quarter, we returned capital to shareholders and repurchased approximately 1.8 million shares of common stock for $50 million, bringing the full-year total of repurchase activities to 3.2 million shares of common stock for $100 million. Moving forward, we expect to continue to opportunistically repurchase shares under the remaining share repurchase program authorization of $150 million. Our strong balance sheet allows us not only to execute on return of capital but also maintain financial flexibility to execute on business development. In the fourth quarter, we closed the acquisition of Zynerba, which was treated as an asset acquisition for accounting purposes. As previously disclosed, we paid approximately $60 million in cash for the closing of the transaction. We received approximately $26 million of cash and $45 million in deferred tax assets from the acquisition and assumed approximately $14 million in liabilities. Thus, we recorded $2.3 million in IP, R&D charge related to the acquisition, along with $7.5 million in one-time restructuring costs. As a result, we were able to acquire two late-stage programs at very attractive deal terms. Going forward, we will recognize considerable operating synergies and expect ongoing incremental costs from the Zynerba development program of approximately $30 million for 2024. Turning to 2024 guidance, for the full year, we expect net revenues of $700 million to $720 million. This range reflects our thoughtful and balanced approach to providing guidance for the first time in company history. It also highlights that we're well on our way towards the billion-dollar opportunity in adult narcolepsy alone that we have consistently communicated and remain confident in. And finally, a comment on seasonality as you think about the phasing of revenue for the first quarter of 2024. We expect to see the typical seasonal dynamics that the industry as a whole experiences each year in Q1, higher gross to net deductions due to insurance plans reset, and higher copay obligations along with a drawdown in trade inventories. In conclusion, we're very pleased with our strong financial performance in 2023 and remain well-positioned to continue growth in 2024 and beyond. We look forward to leveraging our financial strength as we continue to expand and diversify the portfolio while also returning capital to shareholders through our share repurchase program. And with that, I'd like to turn the call back to Jeff for his closing remarks. Jeff?

Thank you, Sandip. In summary, Harmony continues to be a growth story as evidenced by the significant progress our team made in 2023. Looking ahead, we see durability in our core business, strong momentum in our development programs, and remain focused on continuing to grow our WAKIX business and helping even more adult patients living with narcolepsy; advancing our pipeline across both our pitolisant and ZYN002 clinical development programs; working with our partner Bioproject on next-gen formulations to extend the pitolisant franchise to help even more patients living with rare neurological diseases; continuing to build out our pipeline through business development to create a robust portfolio of rare disease assets, covering all stages of development; and deploying capital to maximize shareholder value through our share repurchase program and business development opportunities. I am excited for what is to come this year and believe that we are poised to accelerate Harmony's growth in 2024. This concludes our planned remarks for today. Thank you for joining our call. And I will now turn the call back over to the operator to facilitate the Q&A session. Operator, can you please open the call to questions?

We'll take our first question from Ami Fadia with Needham & Company.

Thank you for giving all the updates on the pipeline. Firstly, I have two questions. First, can you talk about the two new pitolisant formulations on which you're going to be sharing data in the first half? What should we expect to see from the data? And just to set up expectations for investors, will we be able to get visibility into how these formulations may be differentiated from WAKIX based on that data? And then the second question is regarding idiopathic hypersomnia. If you could share any additional color on the analysis that you've put together for your meeting with the FDA? And if you could comment on whether there's any possibility of generating any additional data from the open-label portion of the study to support an approval?

I'll ask Kumar to comment on the next-gen formulations and some visibility there as well as our preparation for the FDA meeting on IH. Kumar?

In terms of next-gen formulation, as we mentioned, we made significant progress on next-gen formulations last year, and we were really pleased to bring both of those two formulations into the clinic in the fourth quarter. As we previously said, we will provide data from the next-gen formulations in the first half of this year. In terms of Next Gen 1 or NG1, it's a modified pitolisant formulation with the potential for clinical differentiation and a first-to-market strategy by demonstrating bioequivalence alongside a clinical study that will offer a meaningful clinical differentiation for patients. The nature of the clinical study and the potential differentiation that will be offered will be discussed at the next earnings call along with the PK data. With the next-gen 2 or NG2 formulation, it's an enhanced formulation of pitolisant designed to deliver optimized pharmacokinetics and also an ability to go to a higher dose strength. This is the formulation that will have a full development program and new IP and is expected to extend the pitolisant franchise well beyond 2040. We plan to provide the pharmacokinetic data from these formulations at our next earnings call. Regarding your question about idiopathic hypersomnia, the totality of the data from the open-label study, the randomized withdrawal period of the study, and the long-term extension study supports pitolisant's efficacy in patients with idiopathic hypersomnia. In terms of the arguments or the discussions that we will be having with the FDA, it's the totality of the data, the non-scheduled start-up of pitolisant, the ease of administration, relatively benign safety profile, especially in the context of only one drug that happens to be a Schedule III controlled substance and the off-label use of Class II controlled substance drugs that have their own safety profile. So all these factors offer a strong benefit-risk proposition to bring pitolisant to patients with idiopathic hypersomnia and we hope to have good discussions with the FDA and find an efficient path forward to bring pitolisant to patients with idiopathic hypersomnia as soon as possible.

Congratulations on a good year in '23. I have one commercial question and then a pipeline question to follow. So regarding the commercial question, absolutely appreciate the ‘25 revenue guidance. Looks good to me. I note that you've added about 350 patients on WAKIX per quarter for the last three quarters, and that seems to be just a really consistent number. And I guess I'm wondering if you could speak to anything in the market dynamics or prescriber access that results in that 350 or if that is just serendipity?

I think, you know, Jeff Dierks can provide some color on the patient adds and the continued market opportunity for WAKIX.

We've been extremely pleased with the durable growth that we've seen in the average number of patients on WAKIX. And I think some of the things that we're seeing Charles is given the unique and meaningfully differentiated product profile, WAKIX has the ability and our sales team has the ability to engage with the broad 9,000 approximate healthcare professionals that see and treat narcolepsy patients. What that does is afford us the opportunity to tap into the full diagnosed patient opportunity, both those individuals and healthcare professionals outside the oxybate REMS program, where we continue to see meaningful growth in the number of unique writers every quarter but even within the oxybate REMS enrolled healthcare professionals, even with the availability of generic and once-nightly oxybate launches this year, we're seeing meaningful growth in terms of depth of prescribing in that audience. So I think really what we're seeing is the unique nature of the meaningfully differentiated product profile and the non-scheduled status, coupled with the broad clinical utility that Jeff Dayno spoke about. That really affords us the ability to continue to tap into that broad diagnosed patient opportunity as the market allows around the traditional quarterly dynamics that we speak about each earnings call. But Charles, we're extremely pleased with what we're seeing and I am hearing from you as well, and we're confident in continued growth in the average number of patients as we move into ‘24.

Quick question on the pipeline, actually a multi-part question. Sorry about that. And that is, appreciate the Phase 3 TEMPO study data, or not data, details. I'm wondering when you would anticipate data, how rapidly do you think that study can enroll, given some competing programs? Is the NDA, sNDA timing, I assume it would be gated by the open-label extension or would you file perhaps before that's completed? And then the second part of the question is regarding the pediatric narcolepsy and priority review. It seems to say something about the agency's perspective on the safety of the product. So I'm wondering if you could provide any thoughts on that and the recent priority review being granted?

Charles, first let me say, I think that we're excited to be initiating the Phase 3 TEMPO study in patients with Prader-Willi. I'll have Kumar comment on that and then I'll circle back on some thoughts about the priority review for the pediatric narcolepsy sNDA. Kumar?

Regarding the PWS study, first of all, we are very pleased to have the orphan drug designation from the FDA for PWS program. In terms of recruitment, we anticipate completing enrollment in about two years. It is true, Charles, that there are multiple programs in this space, but then we are the only ones who are looking at excessive daytime sleepiness and the behavioral symptoms in PWS. The other programs are targeting more towards hyperphagia in PWS. And as we have mentioned previously, more than half of the patients with PWS have excessive daytime sleepiness and almost all of these patients have behavioral disturbances. And from our proof-of-concept study, we showed strong data supporting pitolisant's efficacy both in excessive daytime sleepiness.

Charles, can you repeat that second question about the pediatric narcolepsy sNDA?

The pediatric narcolepsy, PDUFA and rapid time to respond just seems to say something about the safety of the product or the agency's perspective on that, and I'm not speaking for the agency, of course, but that combined with the priority review. I guess do you have any thoughts about their perspectives on that?

Charles, I mean what I would say, I think that as we've shared this week, we're very pleased with the interactions we've had with the FDA regarding the orphan drug designation for pitolisant for Prader-Willi and then followed by the decision for priority review for the pediatric narcolepsy sNDA. I think that it reflects our overall benefit-risk profile of pitolisant and what we have said all along and advancing the development programs. We don't have any concern with regards to the safety profile, which has been consistent from the original pivotal development program in narcolepsy and on through the life cycle management programs that we've been conducting with no real change in the overall safety profile and the favorable benefit-risk profile. I think that reflects the positive interactions we've had with the agency, the decisions that we've received. And we remain focused on the execution and advancement of those development programs to bring potential new treatment options to those patient populations.

So just wondering in terms of the guidance, can you help us understand what the thought process was behind giving guidance for the first time here? And how should we be thinking about the revenue for patients in 2024?

Sandip?

I mean, our guidance represents what I'd say is a thoughtful and balanced approach, especially the first year as we've given guidance. I think we certainly look for opportunities to provide an update as we go throughout the year with respect to the guidance.

How we should think about pricing or maybe revenues per patient's…

I think we did take our price increase earlier this year; it was about 7%, a good portion of that usually follows through to the bottom line. So I think generally, you'll see an impact from that as we go throughout the year. Obviously, in the first quarter, there's usually headwinds regarding gross-to-net pressures and normal things that happen typically in the seasonality that happened. So you generally don't see as much of that in the first quarter. But generally, as we go throughout the year, you'll see the benefit. It's very similar to the pattern that we've had over the last three or four years.

So just a couple first, regarding business development. I wanted to get more detailed thoughts on the extent to which you do a larger-scale transaction versus something smaller scale along the lines of Zynerba. Just philosophically, how are you thinking about acquisitions in general? And tied to that question is also would you lever up and lever up significantly to do something? So that's number one. And then number two, wanted to pick your brain on the orexins. We've seen some data from Takeda, from Alchemies. There are others of course. Wanted to get your view on the potential long-term impact of the orexin receptor agonists, to the extent one or more reach the market?

I think with regards to business development, we are assessing the landscape very actively and we're open to sort of all opportunities. And with regards to a deal similar to Zynerba, that's a good strategic fit, as well as something more transformational. We're in a strong sort of financial position to transact. So we first looked for good strategic fit, prefer sort of late-stage assets but are open to earlier stage, and those that could launch both during the WAKIX life cycle and after. In terms of capacity, I'll ask Sandip to comment on that.

We have good financial strength and flexibility to execute on business development. We also have access to debt if appropriate as well as the capital markets. As also we mentioned, we had over $425 million of cash and cash equivalents available. We're generating significant positive cash flow. Last quarter was about $77 million in cash flow generation, as well as almost over $219 million last year in cash generation. So I think we have a good flexibility, as Jeff mentioned, to look at both small add-on transactions as well as potentially something that's larger and transformative. But I think the important thing is the filter that Jeff mentioned upfront in terms of making sure it's a good strategic fit for the company. From a capital perspective, we have broad flexibility.

And David, turning to your question about the orexin agonist, I mean, you know this space well as do we and we're following it closely. Obviously, a lot of attention lately given some of the data that has come out. I think at a high level the programs are still early, and they're obviously advancing. I think questions are being generated, both on the safety side and the efficacy side based on the data that has been coming out. The target is interesting in terms of the next potential novel mechanism of action for narcolepsy and other central disorders of hypersomnolence. So I think we are following the space closely as the data come out, as more questions have been generated. I think that they likely come to market as successful towards the end of the decade, towards the end of the WAKIX life cycle. But importantly, it's our belief that narcolepsy will continue to be a polypharmacy market; new entrants can only help the space and more share of voice, more education. So interesting novel target, I think it's a way to be seen as these development programs advance. And we'll continue to be a polypharmacy market and we'll follow them as things go forward.

We'll take our next question from Jason Gerberry with Bank of America.

This is Bhavan on for Jason. Our first question is with regards to Zygel assets. Where are you at with enrollment for the Phase 3 Fragile X syndrome study? And any added clarity as to what assumptions shape your view on mid-2025 readout timing? And then the second commercial question, what are your assumptions for average revenue per WAKIX patient? Is that a meaningful tailwind for revenue growth in 2024 in your guidance, or is growth mainly driven by volume?

I'll ask Kumar to comment on the ZYN002 Phase 3 RECONNECT trial. Very exciting opportunity for us and to provide kind of some more color on where we are there.

So we looked at the timeline and as we've mentioned previously, we will. Based on the historical recruitment plan and the anticipated recruitment in this particular patient population, we arrived that we will complete enrollment in the first quarter of 2025 and the top-line will be in mid-2025. Now that the asset is within the half, we will bring all the additional resources and the expertise not just from a clinical development perspective but also from the advocacy group perspective as well to try and accelerate the recruitment.

In terms of revenue per patient, Jeff Dierks, do you want to comment on that?

So in looking ahead in '24, question in terms of just price volume or average revenue per patient. As Sandip shared, we took a 7% price increase in the beginning of the year. And as with previous years, we would expect to capture most of that price increase. As you're looking at our guidance right from 700 to 720, you could see that we're expecting 20 plus percent growth. So you could see that the vast majority of the growth we're expecting in '24 is driven by volume. We've talked a lot about the large remaining diagnosed patient opportunity, the meaningfully differentiated product profile for WAKIX. So we see significant opportunity and room for growth. But hopefully that provides a little bit of context and helps you think about price versus volume assumptions in the average revenue per patient in '24.

And if I could have one follow-up question. What does the appetite for share buybacks in 2024 look like relative to the $100 million in share buybacks that you guys did in 2023?

I think as we said, we're looking to take an opportunistic approach. And Sandip, do you want to comment further?

We're very pleased last year that we were able to do approximately $100 million in share repurchase activities over the last couple of quarters. And I think it's really not a question of either or; we have the flexibility to do both. With respect to business development, we obviously talked about our strategy there. And in terms of the share buyback, again, we'd look at it more opportunistically, and at the appropriate level, we would certainly have a great cash position to be able to execute. And we have approximately $150 million of capacity still remaining.

I was also hoping you could provide some more color on the assumptions that went into your guidance for 2024, specifically around expectations for patient adds. It looks like you're expecting a slowdown in net patient adds each quarter. Are you just being conservative here, or is growth starting to moderate? And then as a follow up, can you remind us what impact label expansion into the pediatric narcolepsy population will have on the overall TAM for WAKIX?

Regarding the revenue guidance, Sandip, would you like to elaborate?

I think as we mentioned, we've taken a thoughtful and balanced approach in terms of providing guidance for the first year. We certainly look to provide an update as we go throughout the year. We're not in any way indicating we see great momentum coming out of the fourth quarter and we expect that momentum to sort of carry through for the year. I mean, Jeff Dierks, do you want to comment at all in terms of just overall growth, what you're seeing?

And Danielle, in terms of looking at average patient growth and sort of the assumptions in the ‘24 guidance. I mean, as you've seen, we've seen demonstrated durable growth in a narcolepsy market and we've grown average patients every quarter since launch, even with availability. But within that durable growth, that growth has evolved every year. And entering our year five of our orphan launch, we're going to expect that growth to continue to evolve but follow the previous year's cadence of the quarterly growth as we tap into that large diagnosed patient opportunity. So you'll see the traditional payer headwinds in the first quarter that impact all brands and specialty products. You'll see the traditional fewer patient visits associated with chronically managed conditions and diseases in Q3. And then typically in previous years, we expect to have the traditional tailwinds in the second and the fourth quarter with stronger prescription demand again. But I think though the takeaway is we're extremely pleased with what we're seeing, confident continued growth, and we really believe that WAKIX is well-positioned for future growth in ‘24.

And your next question on pediatric narcolepsy, that sNDA. It's also important to note that we're pursuing pediatric exclusivity, which is obviously an important commercial opportunity with regards to an additional six months of regulatory exclusivity. So those data are one component of that along with the data that we’ll be generating in the Phase 3 Prader-Willi TEMPO study. Both of these components are important. We are advancing both of these and making progress in terms of pediatric narcolepsy data through that submission and then the initiation of the Phase 3 trial in Prader-Willi syndrome. Both of those components are sort of what would be required as we pursue pediatric exclusivity and additional six months of protection.

This is Avantika on for Graig. I just have a question about the - one about the Fragile X opportunity. I know you said that the timeline has been pushed a little bit due to enrollment. But were there any changes in the trial design as there originally were, which also caused delays? And then also on the pediatric opportunity, I know you said it's a pretty small opportunity. But do you anticipate growing the WAKIX sales force at all if approved?

With regards to the Fragile X study, Kumar?

With Fragile X syndrome, the timelines were not pushed out with that. We had mentioned that we will evaluate the timelines once the asset is in house and we had an opportunity to evaluate the timelines. Based on the historical recruitment plan and the anticipated recruitment in this patient population, we arrived at completing the enrollment in the first quarter of 2025 and the top line anticipated in mid-2025. And there is no change in the study design.

And I would just add. I think that the opportunity is for Harmony, for us to put our resources towards driving the Phase 3 RECONNECT trial forward. With regards to the experience of the clinical development team, more capacity from an operational perspective, and really engaging with the patient community through our patient advocacy efforts as well to drive that forward towards a significant market opportunity of 80,000 diagnosed patients in the US. Turning to pediatric narcolepsy, we keep here in sort of small market opportunity but an important one. And I think Jeff sort of alluded to this, an important one in terms of potential new non-scheduled treatment option for pediatric patients with narcolepsy rather than Schedule II stimulants. So we are looking forward to working with the agency towards that. And then with regards to the impact on the market opportunity, Jeff?

So in looking at the sales force coverage for pediatric narcolepsy, we believe that we're optimized for the narcolepsy opportunity with our existing sales force footprint. There will be some new prescribers that we’ll be adding to our target list if successful. But we believe that our current team that is very excited about the potential to bring this forward is optimized to be able to take on this new opportunity with these additional patients. With the addition of a handful of healthcare professionals, there's a high overlap between adult narcolepsy prescribing and pediatric narcolepsy prescribing. So we believe we've got relationships established with a good portion of those prescribers, but we are absolutely optimized with our team and if successful, very excited to bring this new indication forward.

And can I just squeeze in one more. For gross to net, I know you said that there will be headwinds in the first quarter. But can you just quantify what you think it will be for the full year?

Sandip?

As I mentioned, typically in the first quarter across the industry, there are general headwinds from just higher copay obligations and insurance plan resets in the first quarter. So we'll see a couple of percentage points impact from that typically is what we've seen in the past in the first quarter, and that sort of improved as we go throughout the year generally.

Thank you, Brittany. And thanks everyone for joining our call today and for your interest in Harmony. As you heard from us this morning, our strong execution in 2023 and solid momentum going into this year positions Harmony well for continued growth in 2024. We look forward to providing updates as we execute on our growth strategy. Thank you, and have a great day.

This does conclude today's Harmony Biosciences fourth quarter and full year 2023 financial results conference call. You may now disconnect your line and have a wonderful day.